Dataset Information

Human bone marrow adipocytes display distinct immune regulatory properties.

ABSTRACT:

Background

The bone marrow (BM) is a major reservoir of resting memory T cells and long-lived plasma cells, capable of providing protection against recurrent infections. Whether the age-related accumulation of adipose tissue in the BM affects the functionality and maintenance of memory cells is not well understood.

Methods

For the first time, we compare human femur marrow adipose tissue (fMAT) and subcutaneous white adipose tissue of the thigh (tsWAT) obtained from the same donors. Therefore, we used microarrays for comparative global gene expression analysis, and employed assays to analyse parameters of adipocyte biology, inflammation and oxidative stress.

Findings

We show that fMAT adipocytes differ significantly from tsWAT adipocytes regarding specific gene expression profiles including inflammatory responses and adipogenesis/adipocyte phenotype. Concomitant with considerably lower levels of CD36, a membrane-associated protein important for long-chain fatty acid uptake that is used as maturation marker, fMAT adipocytes are smaller and contain less triglycerides. fMAT adipocytes secrete similar levels of adiponectin and leptin as tsWAT adipocytes, and express increased levels of pro-inflammatory molecules concomitant with an elevated generation of reactive oxygen species (ROS) and impaired function of plasma cells in the BM.

Interpretation

Our findings suggest that fMAT is a unique type of adipose tissue containing small adipocytes with lower CD36 protein and triglyceride levels than tsWAT but high adipokine secretion. Moreover, fMAT adipocytes secrete high levels of pro-inflammatory cytokines, contributing to inflammation and impairment of plasma cell function in the BM, suggesting that fMAT has more immune regulatory functions than tsWAT.

SUBMITTER: Miggitsch C

PROVIDER: S-EPMC6711052 | biostudies-literature | 2019 Aug

REPOSITORIES: biostudies-literature

ACCESS DATA

Publications

Human bone marrow adipocytes display distinct immune regulatory properties.

Miggitsch Carina C Meryk Andreas A Naismith Erin E Pangrazzi Luca L Ejaz Asim A Jenewein Brigitte B Wagner Sonja S Nägele Fabiana F Fenkart Gabriella G Trieb Klemens K Zwerschke Werner W Grubeck-Loebenstein Beatrix B

EBioMedicine 20190718

<h4>Background</h4>The bone marrow (BM) is a major reservoir of resting memory T cells and long-lived plasma cells, capable of providing protection against recurrent infections. Whether the age-related accumulation of adipose tissue in the BM affects the functionality and maintenance of memory cells is not well understood.<h4>Methods</h4>For the first time, we compare human femur marrow adipose tissue (fMAT) and subcutaneous white adipose tissue of the thigh (tsWAT) obtained from the same donors ...[more]

PMID: 31327694

Similar Datasets

Project description:Mesenchymal stem cells (MSCs) affect diverse aspects of tumor progression, such as angiogenesis, tumor growth and metastasis. Bone marrow MSCs (BM?MSCs) are fibroblast?like cells with multipotent differentiation ability, that localize to areas of tissue damage, including wounds and solid tumors. The tumor suppressor gene, p53, is functionally involved in cell cycle control, apoptosis and genomic stability, and is mutated and inactivated in most human cancers. The present study aimed to investigate the role of p53 in the biology of BM?MSCs. In the present study, p53 wild?type (p53+/+), knockdown (p53+/?) and knockout (p53?/?) mouse BM?MSCs (mBM?MSCs) were observed to be similar in appearance and in the expression of cell surface biomarkers, but expressed differential p53 protein levels. The p53+/? and p53?/? mBM?MSCs demonstrated an increased proliferation rate compared with mBM?MSCs derived from p53+/+ mice. mBM?MSCs from all three groups, representing distinct p53 statuses, were unable to form tumors over a 3?month period in vivo. The adipogenic and osteogenic differentiation of mBM?MSCs was increased in the absence of p53. The colony formation and migratory abilities of p53+/? and p53?/? mBM?MSCs were markedly enhanced, and the expression levels of stem cell?associated proteins were significantly increased compared with p53+/+. The expression levels of microRNA (miR)?3152 and miR?337 were significantly increased in p53+/? and p53?/? mBM?MSCs, whereas the expression levels of miR?221, miR?155, miR?1288 and miR?4669 were significantly decreased. The expression levels of tumor necrosis factor?? and interferon???inducible protein?10 were significantly upregulated in the supernatant of p53+/? and p53?/? mBM?MSCs. Ubiquitin protein ligase E3 component n?recognin 2, RING?finger protein 31 and matrix metalloproteinase 19 were highly expressed in p53+/? and p53?/? mBM?MSCs. The results of the present study indicated that p53 may serve an important role in the biology of mBM?MSCs, and may provide novel insights into the role of cells with different p53 statuses in cancer progression.

Project description:BackgroundSystemic inflammation is the main factor underlying secondary osteoporosis in patients with rheumatoid arthritis (RA). Janus kinase inhibitors (JAKi), such as tofacitinib (Tofa), can control systemic inflammation and may have beneficial effects on bone in various models. This might be due to direct effects on the bone microenvironment and not exclusively based on their anti-inflammatory function. Bone marrow adipocytes (BMAds) are abundant in the bone microenvironment. The effect of JAKi on BMAds is unknown, but evidence suggests that there is competition between human bone marrow-derived stromal cell (hBMSC) differentiation routes towards BMAds and osteoblasts (Ob) in osteoporosis.ObjectivesThe aims of the study are to determine whether Tofa influences BMAds and Ob derived from hBMSCs and to investigate the potential effects of Tofa on bone marrow adiposity in RA patients.MethodsTo determine the effect of Tofa on cellular commitment, hBMSCs were differentiated to BMAds or OBs for 3 days together with Tofa at 200, 400, or 800 nM and TNFα. This study was also conducted using differentiated BMAds. The impact of Tofa was determined by gene and protein expression analysis and cell density monitoring. In parallel, in a pilot study of 9 RA patients treated with Tofa 5 mg twice a day (NCT04175886), the proton density fat fraction (PDFF) was measured using MRI at the lumbar spine at baseline and at 6 months.ResultsIn non-inflammatory conditions, the gene expression of Runx2 and Dlx5 decreased in Ob treated with Tofa (p <0.05). The gene expression of PPARγ2, C/EBPα, and Perilipin 1 were increased compared to controls (p <0.05) in BMAds treated with Tofa. Under inflammatory conditions, Tofa did not change the expression profiles of Ob compared to TNFα controls. In contrast, Tofa limited the negative effect of TNFα on BMAd differentiation (p <0.05). An increase in the density of differentiated BMAds treated with Tofa under TNFα was noted (p <0.001). These findings were consolidated by an increase in PDFF at 6 months of treatment with Tofa in RA patients (46.3 ± 7.0% versus 53.2 ± 9.2% p <0.01).ConclusionTogether, these results suggest a stimulatory effect of Tofa on BMAd commitment and differentiation, which does not support a positive effect of Tofa on bone.

Dataset Information

Human bone marrow adipocytes display distinct immune regulatory properties.

Background

Methods

Findings

Interpretation

Publications

Human bone marrow adipocytes display distinct immune regulatory properties.

Similar Datasets

OmicsDI is part of the ELIXIR infrastructure

Tweets